Article Summary
吴艳巧1 严莉2 刘尊敬2 任丽3.74 例急性脑卒中合并糖代谢异常患者治疗及预后的前瞻性研究[J].现代生物医学进展英文版,2012,12(26):5091-5093.
74 例急性脑卒中合并糖代谢异常患者治疗及预后的前瞻性研究
The Prospective Study on Treatment and Prognosis of 74 Cases of Patientswith Acute Stroke and Blood Sugar Metabolism Anomalies Complication*
  
DOI:
中文关键词: 急性脑卒中  血糖代谢异常  前瞻性研究
英文关键词: Acute stroke  Blood glucose metabolic abnormalities  Prospective study
基金项目:
Author NameAffiliation
WU Yan-qiao1, YAN Li2, LIU Zun-jing2, REN Li3 中国石油勘探开发研究院卫生所内科 
Hits: 803
Download times: 832
中文摘要:
      目的:探讨急性脑卒中患者血糖代谢异常的治疗方法及其对预后的影响。方法:抽取我院于2010年1月-2011年10 月收治 的74例急性脑卒中血糖代谢异常患者, 按照入院时间先后将其分为对照组和实验组,其中对照组34 例给予常规溶栓抗凝和抗 血小板治疗,实验组40例行给予胰岛素联合溶栓抗凝和抗血小板综合治疗。对所有患者进行1-2个月的随访,对比两组患者的临 床疗效和空腹血糖变化。结果:两组间治疗前相比,空腹血糖值差异无统计学意义(P>0.05);两组间治疗后相比,实验组患者的空 腹血糖值(5.76±1.09)低于对照组(9.36±1.66),比较差异有统计学意义(P<0.05)。两组间相比,实验组患者的总有效率为97.5%, 高于对照组的88.2%,统计学差异有意义(P<0.05)。实验组患者神经功能缺损评分(NDS)为39.4±2.4、格拉斯哥昏迷评分(GCS) 为9.2±1.6 和日常生活活动能力(ADL)为5.4±1.2 均高于对照组(27.7±1.4、6.4±1.2、3.8±1.3),比较差异有统计学意义(P<0. 05)。结论:运用诺和灵、血栓通、奥扎格雷联合治疗急性脑卒中合并血糖代谢异常,可有效地改善患者的血糖变化和脑部功能。
英文摘要:
      Objective: To study the therapeutic method for patients with acute stroke and blood sugar metabolism anomalies and its effect on prognosis. Methods: From March 2011 to January 2012, 74 cases of patients with acute stroke and secondary glucose metabolism abnormal in our hospital were selected as the object of study. According to the inhospital time order, all patients were divided into the control group and the experimental group. 34 patients in the control group were given conventional treatments, and 40 patients in the experimental group were given the novolin, Xueshuantong injection and ozagrel combination therapy. After 1 to 2 months of follow- up for all patients, we compared the clinical curative effect and the fasting blood sugar changes of the two groups. Results: Before treatment, the fasting blood sugar value showed no statistically significant differences between the two groups (p>0.05); After treatment, the fasting blood sugar value of the experimental group (5.76 ±1.09) was lower than those of the control group (9.36 ±1.66), with statistically significant difference (P<0.05). Between the two groups, the total effective rate of the experimental group was 97.5%, which was higher than those in the control group (88.2%); the difference was statistically significant (P<0.05). Of the experimental group, the neural function defect score (NDS) was 39.4±2.4, Glasgow coma scale (GCS) was 9.2±1.6 and daily life activities (ADL) was 5.4±1.2, all of which were higher than those in the control group(27.7±1.4, 6.4±1.2, 3.8±1.3 respectively); the difference were statistically significant (P<0.05). Conclusion: The novolin, Xueshuantong injection and ozagrel combination therapy for acute stroke combined with glucose metabolism abnormal can effectively improve the blood sugar metabolism change and brain function.
View Full Text   View/Add Comment  Download reader
Close